Awards Registry

Reactive oxygen species and ultraviolet light damage
Profile last edited on: 4/17/02

Total Award Amount
Award Phase
Principal Investigator
John W Dietrich
Activity Indicator

Company Information

Abeona Therapeutics Inc (AKA:PlasmaTech Biopharmaceutcials Inc~Access Pharmaceuticals Inc~Chemex Corporation~Chemex Pharmaceuticals Inc)

1330 Avenue of the Americas 33rd Floor
New York, NY 20029
   (214) 905-5100
Multiple Locations:   
Congressional District:   32
County:   Dallas

Phase I

Phase I year
Phase I Amount
Chemex Pharmaceuticals, Inc 's, nordihydroguaiaretic acid (CHX 100) is a potent antioxidant also possessing antiproliferative, antitumor, and lipoxygenase inhibition activities. These actions, especially its antioxidant and lipoxygenase inhibitory activities, suggest that CHX 100 may reduce the deleterious effects of acute ultraviolet light (WL) exposure on the skin, as these effects may be associated with formation of reactive oxygen species (ROS). Such effects include erythema, edema, and damage to the epidermal keratinocyte and melanocyte. In addition, the reported ability of CHX 100 to attenuate tumor development in a murine model of skin tumor initiation and promotion suggests the drug could prevent some of the deleterious effects of chronic sun exposure, such as the development of precancerous and cancerous lesions. The goal of this study is to evaluate the role of ROS in WL-induced damage to skin cells and the ability of CHX 100 and ROS scavengers to prevent this damage. The specific aims are to determine:(1) the effects of WL on arachidonic acid release from, and viability of, cultured human keratinocytes and the ability of CHX 100 and ROS scavengers to alter this response; and(2) the ability of CHX 100 and ROS scavengers to attenuate WL-induced melanocyte hyperplasia and hyperpigmentationAwardee's statement of the potential commercial applications of the research:The general population is becoming more aware of the adverse effects of sun exposure, with sales of sunscreens in the United States in excess of $100 million. Presently available sun protectants have possible longterm side effects. This research is aimed at developing safe, effective topical drugs for the prevention of skin damage associated with acute and chronic sun exposureNational Cancer Institute (NCI)

Phase II

Phase II year
Phase II Amount